Anjanette Varnado, MD
Family Medicine · Greensburg, LANPI 1003025347
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 27.5% of the total. Reporting peaked in 2023 at $794 and has fallen 93.4% since, to $53 in 2025.
Across 157 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$857
- AbbVie$589
- Abbott$428
- Pfizer$286
- Takeda Pharmaceuticals U.S.A., Inc.$229
- Novartis$124
- plus $609 from 11 others
What the payments were for
- Food & beverage$3,122100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 57 | $857 |
| AbbVie(2 entities) | 35 | $589 |
| Abbott | 3 | $428 |
| Pfizer | 15 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $229 |
| Novartis | 7 | $124 |
| GSK | 6 | $100 |
| Bayer | 3 | $98 |
| Lilly USA, LLC | 5 | $85 |
| Merck | 4 | $83 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 5 | $57 |
| Boehringer Ingelheim | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOT DX$178
- VRAYLAR$126
- CardioMEMS HF System$125
- CARDIOMEMS$125
How this compares
$3,122 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 124 | $139,522 |
| JanuviaSitagliptin Phosphate | 123 | $103,589 |
| LinzessLinaclotide | 140 | $79,880 |
| OzempicSemaglutide | 70 | $71,144 |
| EliquisApixaban | 136 | $70,499 |
| JardianceEmpagliflozin | 46 | $37,857 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $23,931 |
| FarxigaDapagliflozin Propanediol | 36 | $20,381 |
| XareltoRivaroxaban | 45 | $17,811 |
| MyrbetriqMirabegron | 43 | $13,979 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $13,185 |
| Spiriva RespimatTiotropium Bromide | 21 | $10,761 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $9,752 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,613 |
| TradjentaLinagliptin | 16 | $8,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $85 | $139,522124 claims |
| MerckJanuvia, Janumet | $83 | $113,340141 claims |
| AbbVieLinzess | $589 | $79,880140 claims |
| PfizerEliquis, Premarin | $286 | $76,349163 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $36 | $56,81783 claims |
| GSKTrelegy Ellipta | $100 | $23,93137 claims |
| Johnson & JohnsonXarelto | $14 | $17,81145 claims |
| Sanofi-aventis U.S. LLCLantus | $79 | $2,17031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Greensburg
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
- Richard JeansonneMandeville$49K
- Leonard TreanorHammond$29K
- Shannon HaasMandeville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.